neovascular glaucoma
Conditions
Interventions
Injection group:Intravitreal Ranibizumab 0.5 mg / 0.05 ml
Control:Without intravitreal Ranibizumab
Sponsors
Shanghai First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. neovascular glaucoma patients with age between 18 and 85 years old; 2. intraocular pressure higher than 22 mm Hg (1 mm Hg = 0.133 kPa, Goldmann applanation tonometry) with additional anti-glaucoma medicines; 3. with or without intravitreal Ranibizumab 0.5 mg/0.05 ml from 1 to 5 days before Ahmed glaucoma valve implantation; 4. to finish at least 6 months follow-up.
Exclusion criteria
Exclusion criteria: 1. with other type of glaucoma or other serious ocular disease; 2. previous anti-glaucoma surgery or other intraocular surgery; 3. previous intravitreal injection within 3 months; 4. less than 6 months follow-up; 5. difficult to measure intraocular pressure; 6. combined with cataract surgery or vitreal surgery; 7. binocular surgery or intravitreal injection; 8. pregnant or with uncontrolled internal medicine disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| intraocular pressure;surgical success rate;best corrected visual acuity; | — |
Secondary
| Measure | Time frame |
|---|---|
| additional anti-glaucoma medicine;operative complications; | — |
Countries
China
Contacts
Public ContactTang Min
Outcome results
None listed